This pilot study examined the effect of adjunctive salsalate on psychopathology and cognition in patients with schizophrenia. This was a 12-week, open-label trial of salsalate (1.5 g, twice per day) in patients with schizophrenia. Psychopathology, cognition, and daily function were assessed at baseline and week 12 using various rating scales. Blood levels of inflammatory markers including white blood cell count, high-sensitivity C-reactive protein, and interleukin-6 levels were also measured. Eight patients completed the study. There was no significant change in any of the rating scales at week 12. However, there was a trend decrease in the Positive and Negative Syndrome Scale total score, and a trend improvement in the Brief University of California San Diego Performance-based Skills Assessment total score (58.3 ± 11.4 vs. 53.5 ± 11.9, P = 0.072; 69.7 ± 18.2 vs. 79.1 ± 15.9, P = 0.084, respectively). There was a trend improvement in quality of life as measured by the Quality of Life Scale total score (74.0 ± 20.8 vs. 76.9 ± 22.7, P = 0.080). There was a significant decrease in white blood cell count (6.8 ± 1.3 vs. 6.0 ± 1.2 k/mm 3 , P = 0.022). There was no change in the levels of high-sensitivity C-reactive protein or interleukin-6 over 12 weeks (P's > 0.1). Salsalate may have positive therapeutic effect in patients with schizophrenia. Future studies to examine potential benefits of salsalate as an adjunctive treatment to improve clinical symptoms and daily function in patients with schizophrenia are warranted. Int Clin Psychopharmacol 33:88-91
Introduction
Patients with schizophrenia tend to have abnormal immune activation resulting in elevated proinflammatory cytokine levels, ultimately leading to functional brain impairments and psychotic symptoms (Mitra et al., 2017) . Cognitive deficits are also considered a core feature of schizophrenia. Increasing evidence suggests that cognitive impairment is associated with inflammatory processes in patients with schizophrenia (Cabrera et al., 2016; Misiak et al., 2017) .
Recent clinical trials suggest that anti-inflammatory agents may have therapeutic effect in schizophrenia treatment. Cyclooxygenage-2 (COX-2) inhibitors such as celecoxib reduce the production of proinflammatory cytokines. It was reported that celecoxib had significant benefit in improving schizophrenia symptoms as measured by the Positive and Negative Syndrome Scale (PANSS) total score (Muller et al., 2002) . Another study in patients with chronic schizophrenia reported that celecoxib significantly reduced the PANSS total score and the positive symptoms subscale score (Akhondzadeh et al., 2007) . In a 6-week trial of celecoxib augmentation to amisulpride treatment in patients with early-stage schizophrenia, the authors reported a significant reduction in the PANSS total score and the negative symptoms subscale score (Muller et al., 2010) . None of these three studies examined the effect of celecoxib on cognitive function. Another commonly used anti-inflammatory agent, aspirin, was also studied in the schizophrenia population. It was reported that aspirin (1000 mg/day) as an adjunctive treatment for 3 months significantly reduced schizophrenia symptoms as measured by the PANSS total score and the positive symptoms subscale score; however, there was no significant improvement in cognitive function (Laan et al., 2010) .
The cardiovascular safety of celecoxib and other COX-2 inhibitors remains uncertain (Solomon et al., 2005; Nissen et al., 2016) ; cardiovascular disease is a serious comorbid medical condition in patients with schizophrenia. The cardioprotective nonselective COX inhibitor aspirin is arguably preferable. However, it is well established that aspirin, especially used in a relatively high dose, is associated with a significant risk of gastrointestinal bleeding (Lanas and Ferrandez, 2002) . Despite the promise of potential benefit of celecoxib and aspirin in schizophrenia treatment, the adverse safety concerns related to these two drugs limit their potential clinical utility in this patient population.
Anti-inflammatory salicylates exist as two different forms: nonacetylated (e.g. sodium salicylate, salsalate, and trilisate) and acetylated (e.g. aspirin). Lacking an acetyl group, nonacetylated salicylates like salsalate do not modify COX enzymes or inhibit platelets, which is likely the difference that minimizes the risk of cardiovascular disease related to celecoxib or the risk of bleeding related to aspirin (Manrique et al., 2008) . Salsalate has been marketed since 1972 as an oral analgesic, antipyretic, and antirheumatic drug. Salsalate has proven to be safe and well tolerated in the general population (Hauser et al., 2016) .
We conducted a 12-week, open-label pilot trial of salsalate (1.5 g, twice per day) as an adjunctive therapy in patients with schizophrenia to examine salsalate's effects on psychopathology, cognition, and daily function.
Patients and methods

Patients
The study was approved by the local institutional review board. Adult outpatients with schizophrenia or schizoaffective disorder were recruited from communitybased mental health clinics. Psychiatric diagnosis was determined using the Structure Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV) (Spitzer et al., 1992) . Other inclusion criteria included the following: (i) age 18-65 years; (ii) stable dose of the current antipsychotic drug for at least 1 month; (iii) able to complete the cognitive assessment battery (must be English speaking); and (iv) for female patients, nonchildbearing potential or childbearing potential but willing to practice appropriate birth control methods during the study. Exclusion criteria included the following: (i) inability to provide informed consent; (ii) current substance abuse; (iii) psychiatrically unstable per treating clinician's judgment; (iv) significant medical illnesses including uncontrolled hypertension, diabetes, seizure disorder, severe cardiovascular, cerebrovascular, pulmonary, or thyroid diseases; (v) currrently on immunosuppressant medication including oral steroids; (vi) use of anticoagulants; (vii) history of long-term infection (including, HIV and hepatitis), malignancy, organ transplantation, blood dyscrasia, central nervous system demyelinating disorder, and any other known autoimmune or inflammatory condition; (viii) pregnancy or breastfeeding; (ix) preexisiting chronic tinnitus; and (x) known hypersensitivity or allergic reaction to salsalate.
Procedure
Potential participants underwent a diagnostic evaluation at the clinic. Psychiatric diagnosis was determined using the Structure Clinical Interview for DSM-IV (Spitzer et al., 1992) . Fasting blood samples for inflammatory biomarkers including white blood cell (WBC) counts, interleukin-6 (IL-6), and high-sensitivity C-reactive protein (hsCRP) were obtained.
On a separate day, eligible participants came to the clinic for baseline visit. Participants completed the clinical assessment battery including the PANSS (Kay et al., 1987) , the Calgary Depression Rating Scale (Addington et al., 1993) , the Quality of Life Scale (QLS) (Heinrichs et al., 1984) , the Brief University of California San Diego Performance-based Skills Assessment (UPSA-B, including communication and finance subtests) (Mausbach et al., 2007) , and the Measurement and Treatment Research to Improve Cognition in Schizophrenia cognitive battery (Nuechterlein et al., 2008) . Adverse effects/ safety assessment included vital signs and the Side Effect Questionnaire. At the end of this visit, the study medication salsalate was dispensed to the patient (500 mg pills, three pills each time, twice per day), which is the Food and Drug Administration recommended dose for osteoarthritis or rheumatoid arthritis treatment). A dosereduction plan was specified a priori with stepped reductions of 500 mg for adverse effects related to salicylate use, such as tinnitus or headache.
Patients had follow-up visits at weeks 2, 4, 6, 8, and 10. Each visit consisted of adverse effects/safety assessment. At the end of each visit, the study medication was dispensed to the patient. At week 12, patients had the last study visit. The visit consisted of adverse effects/safety assessment, and the rating scale assessment. Fasting blood samples for inflammatory biomarkers were obtained.
Laboratory assays
Blood samples were obtained after a 10 h fast. WBC with differential was analyzed using a COULTER LH 750 Hematology Analyzer (Beckman Coulter Inc., Brea, California, USA). hsCRP and IL-6 levels were measured using enzyme-linked immunosorbent assays.
Statistical analysis
Statistical analysis was performed using SPSS (version 24; IBM Corp., Armonk, New York, USA). Descriptive statistics were performed to summarize demographic and clinical characteristics of the study sample. Repeatedmeasures comparisons (baseline vs. week 12) for outcome measures were performed using paired-samples t-test. For all analyses, a P value less than 0.05 (two tailed) was used for statistical significance.
Results
Seventeen participants were screened. Among them, 13 were enrolled and eight completed the study. The results were based on completers only. Of the eight completers, six were male and two female; six were Caucasians and two African-Americans; six were on an atypical antipsychotic agent, one on an typical antipsychotic agent, and one on both typical and atypical agents; and four were on an antidepressive agent, and one on a mood stabilizer. The study sample's age, age of illness onset, disease duration, and years of formal education (mean SD) were 42.8 9.8, 23.3 7.7, 19.6 9.9, 12.3 2.1 years, respectively. Paired-samples t-test analysis shows that none of the rating scale measures had significant change at week 12 compared with the baseline value. However, there was a trend decrease in the PANSS total score (58.3 11.4 vs. 53.5 11.9, P = 0.072, effect size Cohen's d = 0.75). There was also a trend improvement in the UPSA-B total score (69.7 18.2 vs. 79.1 15.9, P = 0.084, Cohen's d = 0.71), mostly reflecting the improvement in the UPSA-B finance subtest score (36.4 8.4 vs. 40.9 8.4, P = 0.067, Cohen's d = 0.77). Furthermore, there was a trend improvement in quality of life as measured by the QLS total score (74.0 20.8 vs. 76.9 22.7, P = 0.080, Cohen's d = 0.72). In addition, there was a significant decrease in WBC levels from baseline to week 12 (6.8 1.3 vs. 6.0 1.2 k/mm 3 , P = 0.022). There was no significant difference in levels of hsCRP or IL-6 over 12 weeks (P > 0.1) ( Table 1) .
Adverse effect assessment
There were no serious adverse events during the study. Reported adverse effects were mild and included abdominal discomfort, nausea/vomiting, lightheadedness, and bloody urine, each by one patient. Two patients reported mild headache.
Discussion
We believe that the present pilot study was the first one to examine potential benefits of adjunctive salsalate treatment for clinical symptoms, cognition, and function in patients with schizophrenia. Even though none of the major outcome measures showed a significant change over the 12-week treatment period, there was a trend decrease in the PANSS total score, and a trend improvement in the UPSA-B total score, the finance subtest score, and the QLS total score. Salsalate was well tolerated; tinnitus, an established adverse effect of salicylates use, was not reported in our study.
Our study also found a significant decrease in WBC count, but no significant changes in hsCRP or IL-6 after 12-week salsalate treatment was reported. WBC count is a nonspecific inflammatory marker. In a previous study, we reported that elevated levels of WBC were associated with more severe schizophrenia symptoms, especially negative symptoms (Fan et al., 2010) . The antiinflammatory effect of salsalate treatment may serve as a mediator for its potential therapeutic benefit for schizophrenia. Owing to the small sample size, we were not able to conduct further analysis to examine the possible mediating role of WBC in improving clinical symptoms and function in our study.
Recent studies suggest that salsalate is a potent inhibitor of nuclear factor-κB (NF-κB) activity, which controls the expression of genes that regulate a broad range of biological processes in the brain, such as apoptosis, synaptic plasticity, neurogenesis, and differentiation (Camandola and Mattson 2007; Yang et al., 2007) . Song et al. (2009) reported that NF-кB activation and its mRNA expression in peripheral blood mononuclear cells were excessively increased in drug-naive, first episode schizophrenia patients compared with healthy controls; the study suggested that NF-κB activation may play a pivotal role in schizophrenia through interaction with cytokines. Even though it was not examined in our study, it is speculated that salsalate may improve schizophrenia symptoms by inhibiting NF-κB activation in addition to its antiinflammatory property.
Our study failed to show a significant therapeutic effect of salsalate on various outcome measures. The absence of a placebo control group further increases the uncertainty of our trend level findings. The small sample size and the relatively short treatment time period (12 weeks) could be among the possible reasons. In addition, the chronicity of illness in our study sample (disease duration: 19.6 9.9 years) might be another reason. A recent review of six studies that examined celecoxib adjunctive treatment in schizophrenia suggested that celecoxib treatment most likely shows beneficial effects in the early stage, rather than the chronic stage of illness (Marini et al., 2016) .
Inflammation also plays an important role in the development of obesity, diabetes, hyperlipidemia, and metabolic syndrome, which are common comorbid medical problems in the schizophrenia patient population (Fan et al., 2007;  Song et al., 2014) . Therefore, a possible added benefit of salsalate treatment is to address metabolic problems in patients with schizophrenia. Goldfine et al. (2010) reported that salsalate improves markers of glycemic control in patients with type 2 diabetes. A 6-week, open-label study in 10 patients with schizophrenia and also with BMI more than 27 kg/m 2 found that adjunctive salsalate treatment (2 g, twice per day) led to a significant reduction in levels of triglycerides and hemoglobin A1c. In addition, there was a trend decrease in levels of various cytokines that are indicative of immune activation (IL-1β, IL-2, and IL-6); the effects of salsalate on clinical symptoms and function were not reported in that study (Keller et al., 2013) .
Future studies with a larger sample size, longer treatment time duration, and double-blind, placebo-controlled design are needed to further examine potential benefits of salsalate treatment to improve psychiatric symptoms and metabolic problems in patients with schizophrenia, especially in the early phase of illness. In addition, future studies need to examine the potential mediating role of NF-кB or other immune/inflammation related biomarkers to predict therapeutic response of salsalate treatment in schizophrenia.
